Cat. No.: HY-164826

Acetyl zingerone

Customer Review

Based on 1 Customer Validation

Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice. Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer.

For research use only. We do not sell to patients.

Purity: 99.34%
CAS No.: 30881-23-3
Formula: C₁₃H₁₆O₄
Molecular Weight:236.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Acetyl zingerone Chemical Structure

CAS No.: 30881-23-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Interleukin Related Isoforms :

All MMP Isoforms :

All Caspase Isoforms :

In Vitro

Acetyl zingerone alters gene expression in recombinant human epidermis, upregulating genes related to the core matrix group, Notch, and ERK1/ERK2 pathways, while downregulating inflammation-related genes, as well as genes associated with the TGF-β signaling pathway and AP-1/NF-κB^[1].
Acetyl zingerone (10-200 µg/mL; 6 days) dose-dependently increases the abundance of extracellular matrix proteins per cell density in cultured human skin fibroblasts^[1].
Acetyl zingerone (10 µL/cm²; once daily for 4 consecutive days) doubles the dermal collagen content in ex vivo human facial skin biopsy samples^[1].
Acetyl zingerone (with 1:1 serial dilutions performed starting from a stock solution prepared by dissolving 0.1 g AZ in 1 mL DMSO; 10 min (MMP-1, MMP-3); 15 min (MMP-12)) inhibits the activities of MMP-1, MMP-3 and MMP-12 in cell-free assays, with the strongest inhibitory potency against MMP-12 (IC₅₀ = 0.255 mg), followed by MMP-3 (IC₅₀ = 0.505 mg) and MMP-1 (IC₅₀ = 1.065 mg)^[1].
Acetyl zingerone reverses gene expression patterns associated with fibroblast senescence, keratinocyte differentiation, and IL-17A stimulation in reconstructed human epidermis^[1].
Acetyl zingerone (25-200 μM; 2-48 h) exerts a protective effect on ATDC5 chondrocytes, protecting them from LPS (HY-D1056)+ ATP (HY-B2176)-induced cytotoxic damage and restoring their proliferative capacity^[2].
Acetyl zingerone (100 μM; 24 h) inhibits LPS + ATP-induced pyroptosis of ATDC5 chondrocytes by alleviating cell membrane damage, suppressing NLRP3 inflammasome activation, and reducing the expression of downstream pyroptosis-related proteins^[2].
Acetyl zingerone (100 μM; 24 h) attenuates LPS + ATP-induced mitochondrial damage in ATDC5 chondrocytes by reducing ROS/mtROS production and restoring mitochondrial membrane potential and structural integrity^[2].
Acetyl zingerone (100 μM; 24 h pretreatment, 24 h LPS + ATP induction) activates PINK1/Parkin-mediated mitophagy in LPS + ATP-treated ATDC5 chondrocytes^[2].
Acetyl zingerone (25-100 μM; 24-48 h) increases the survival rate of primary rat chondrocytes treated with IL-1β and restores their proliferative capacity^[3].
Acetyl zingerone (25-100 μM; 24 h) maintains ECM homeostasis in IL-1β-treated primary rat chondrocytes and mouse ATDC5 chondrogenic cells by upregulating aggrecan and COL2A1, and downregulating matrix-degrading enzymes and inflammatory factors^[3].
Acetyl zingerone (25-100 μM; 24 h) inhibits IL-1β-induced apoptosis in IL-1β-treated primary rat chondrocytes and mouse ATDC5 chondrogenic cells by upregulating Notch1 and SOCS3 and reducing the level of activated caspase-3^[3].
Acetyl zingerone (25-100 μM; 24 h) reduces IL-1β-induced ROS accumulation in primary rat chondrocytes^[3].
Acetyl zingerone (100 μM; 24 h) inhibits IL-1β-induced ferroptosis in primary rat chondrocytes and mouse ATDC5 chondrogenic cells by increasing GSH levels, decreasing MDA levels, stabilizing mitochondrial structure, upregulating GPX4, and activating the Nrf2/HO-1 pathway^[3].
Acetyl zingerone (25 µg/mL; administered 1-6 h post-UVA irradiation) significantly reduces the formation of dark-state cyclobutane pyrimidine dimers (dark-CPD) in melanocytes of C57BL/6 mice within the first 2 hours after UVA exposure, with an inhibition rate of approximately 82% at 1 h post-irradiation, without impairing DNA repair function or cell viability^[4].
Acetyl zingerone (25-50 µg/mL; 20 min pre-incubation prior to 25 min UVA irradiation) dose-dependently reduces UVA-induced ROS production in normal human neonatal epidermal keratinocytes, with reduction rates of 35% and 46%, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[1]

Cell Line:

Cultured human dermal fibroblasts
Concentration:

0, 10, 25, 50, 100, 200 µg/mL
Incubation Time:

6 day
Result:

Increased protein abundance per unit cell density (P < 0.05) in a dose-dependent manner for type I, IV, and VI collagens; fibromodulin; transforming growth factor-β; fibronectin; TIMP-1; and vimentin.
Showed greater abundance with higher AZ concentrations, with significant differences from control observed at specific doses (e.g., type I collagen at 100 µg/mL, type IV collagen at 50 and 100 µg/mL).

Cell Viability Assay^[2]

Cell Line:

ATDC5 chondrocytes
Concentration:

25, 50, 100, 200 μM
Incubation Time:

24 h, 48 h (co-treatment with LPS + ATP); 24 h (treatment with LPS + ATP), 2 h (EdU (HY-118411) incubation)
Result:

Shows no cytotoxicity at concentrations below 100 μM.
Significantly reduces cell viability at 200 μM after 24 h and 48 h.
Mitigates LPS + ATP-induced cytotoxicity, with 100 μM producing the most pronounced improvement in cell viability.
Reverses LPS + ATP-induced inhibition of chondrocyte proliferation, with 100 μM being the most effective concentration.

Cell Autophagy Assay^[2]

Cell Line:

ATDC5 chondrocytes
Concentration:

100 μM
Incubation Time:

24 h pretreatment, followed by 24 h LPS + ATP induction
Result:

Significantly increases the expression of PINK1, Parkin, and LC3-II, and decreases p62 expression in LPS + ATP-treated chondrocytes.
Enhances PINK1 and Parkin expression, which is suppressed by chloroquine (CQ) via immunofluorescence.
Increases co-localization of Parkin and LC3B with mitochondria, enhances autolysosome formation, and promotes mitophagic clearance of damaged mitochondria; these effects are attenuated by CQ.
Reduces LPS + ATP-induced ROS and mtROS production, an effect reversed by CQ.

Apoptosis Analysis^[3]

Cell Line:

primary rat chondrocytes, mouse ATDC5 chondrogenic cells
Concentration:

25, 50 and 100 μM
Incubation Time:

24 h
Result:

Reduced IL-1β-induced apoptosis (lower early + late apoptotic cell proportion), increased cell number, upregulated Notch1 and SOCS3 expression, and decreased the cleaved caspase-3/caspase-3 ratio compared with the IL-1β-treated group.
Flow cytometry confirmed the anti-apoptotic effect at 100 μM, while crystal violet staining and western blot showed dose-dependent effects at 25, 50, and 100 μM.
Produced similar results in mouse ATDC5 cells.

Western Blot Analysis^[3]

Cell Line:

primary rat chondrocytes
Concentration:

100 μM
Incubation Time:

24 h
Result:

Upregulated Nrf2, HO-1, and GPX4 expression compared with the IL-1β-treated group.
Had its protective effect on GPX4 expression abolished by Nrf2 or HO-1 inhibitors, which exacerbated IL-1β-induced GPX4 suppression.

ELISA Assay^[4]

Cell Line:

C57BL/6 mouse melanocytes
Concentration:

25 µg/mL
Incubation Time:

1, 2, 4, 6 h post-UVA irradiation
Result:

Significantly reduced dark-CPD formation within the first 2 h post-irradiation, with an ~82% reduction observed after 1 h compared to controls.
Matched control CPD levels by 6 h post-irradiation, indicating no interference with DNA repair.
Left cell viability unaffected.

In Vivo

Acetyl zingerone (1 mg/kg; intra-articular injection; twice a week; for 8 consecutive weeks) alleviates osteoarthritis progression induced by the destabilization of the medial meniscus (DMM) model in mice by promoting PINK1/Parkin-mediated mitophagy, inhibiting chondrocyte pyroptosis, reducing cartilage damage, and restoring subchondral bone remodeling^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 J (male, 8-week-old, DMM surgery-induced osteoarthritis)^[2]
Dosage:

1 mg/kg
Administration:

intra-articular injection; twice a week; 8 weeks
Result:

Significantly reduced calcified menisci and bone remnants compared to the DMM-only group.
Normalized subchondral bone microarchitecture parameters, increasing bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) relative to the DMM-only group.
Reduced cartilage loss and proteoglycan depletion, lowering Osteoarthritis Research Society International (OARSI) scores compared to the DMM-only group.
Decreased immunohistochemical staining of pyroptosis-related protein NLRP3 and matrix-degrading protein MMP13 in cartilage tissues relative to the DMM-only group.
Increased immunohistochemical staining of mitophagy-related proteins Parkin and LC3B, as well as matrix-synthesizing protein Collagen II, in cartilage tissues relative to the DMM-only group.

Chemical Information

CAS No. 30881-23-3
Appearance Solid
Molecular Weight 236.26
Formula C₁₃H₁₆O₄
Color White to off-white
SMILES

O=C(C(CC1=CC=C(C(OC)=C1)O)C(C)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (423.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2326 mL

21.1631 mL

42.3263 mL

5 mM

0.8465 mL

4.2326 mL

8.4653 mL

10 mM

0.4233 mL

2.1163 mL

4.2326 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (21.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (21.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (21.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Swindell WR, et al. A Zingerone Analog, Acetyl Zingerone, Bolsters Matrisome Synthesis, Inhibits Matrix Metallopeptidases, and Represses IL-17A Target Gene Expression. J Invest Dermatol. 2020;140(3):602-614.e15. [Content Brief]

[2]. Zhang Z, et al. Acetyl zingerone inhibits chondrocyte pyroptosis and alleviates osteoarthritis progression by promoting mitophagy through the PINK1/parkin signaling pathway. Int Immunopharmacol. 2025;161:115055. [Content Brief]

[3]. Chen X, et al. Acetyl zingerone ameliorates osteoarthritis by inhibiting chondrocyte programmed cell death. Mol Med Rep. 2023;28(5):202. [Content Brief]

[4]. Chaudhuri RK, et al. Acetyl zingerone: An efficacious multifunctional ingredient for continued protection against ongoing DNA damage in melanocytes after sun exposure ends. Int J Cosmet Sci. 2020;42(1):36-45. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2326 mL	21.1631 mL	42.3263 mL	105.8156 mL
	5 mM	0.8465 mL	4.2326 mL	8.4653 mL	21.1631 mL
	10 mM	0.4233 mL	2.1163 mL	4.2326 mL	10.5816 mL
	15 mM	0.2822 mL	1.4109 mL	2.8218 mL	7.0544 mL
	20 mM	0.2116 mL	1.0582 mL	2.1163 mL	5.2908 mL
	25 mM	0.1693 mL	0.8465 mL	1.6931 mL	4.2326 mL
	30 mM	0.1411 mL	0.7054 mL	1.4109 mL	3.5272 mL
	40 mM	0.1058 mL	0.5291 mL	1.0582 mL	2.6454 mL
	50 mM	0.0847 mL	0.4233 mL	0.8465 mL	2.1163 mL
	60 mM	0.0705 mL	0.3527 mL	0.7054 mL	1.7636 mL
	80 mM	0.0529 mL	0.2645 mL	0.5291 mL	1.3227 mL
	100 mM	0.0423 mL	0.2116 mL	0.4233 mL	1.0582 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Acetyl zingerone

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Protease Inhibitor Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

All Interleukin Related Isoforms

All MMP Isoforms

All Caspase Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Acetyl zingerone Related Classifications

HY-164826 Related Classifications